International Medical Services
Aktuelles
Das Studienzentrum der Hautklinik sucht Patienten mit
Chronischer spontaner Nesselsucht
– Melden Sie sich –
Das Studienzentrum (CRC - Clinical Research Center) der Hautklinik sucht Studienteilnehmer/ innen ab 18 Jahre, die Interesse an der Durchführung dieser Studie haben. Patienten mit spontan auftretender Nesselsucht oder kälteassoziierter Nesselsucht, welche auf Antihistaminika nicht angesprochen haben.
Sollten Sie Interesse an einer Teilnahme haben, nehmen Sie Kontakt mit uns auf. Weitere Informationen teilen wir Ihnen gerne in einem persönlichen Gespräch mit.
Wir freuen uns auf Ihren Anruf!
Kontakt:
CRC-Studienzentrum/Hautklinik Geb. 401/1.Stock
Universitätsmedizin Mainz, Langenbeckstr. 1, 55131 MainzTelefon: 06131 17-5732
Geschlossen (laufend)
Indikation | Protokollnummer | Titel | Phase |
|---|---|---|---|
Psoriasis vulgaris | Bili1311.4 | BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawl and re-treatment | III |
Psoriasis vulgaris | IM011-011 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | II |
Psoriasis vulgaris | CAIN457A2304E1 | A multicenter, double-blind and open-label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen | III |
Psoriasis vulgaris | PS0003 | A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis | III |
Psoriasis vulgaris | I1F-MC-RHAZ | A multicenter Study with a randomized, double-blind, placebo-controlled Induction dosing period followed by a randomized maintenance dosing Period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe palque psoriasis | III |
Psoriasis vulgaris | CNTO1959PSO3008 | Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm® initial/ Fumaderm®) for adult patients with moderate to severe plaque psoriasis who are candidates for and naive to systemic treatment (POLARIS) | IIIb |
Psoriasis vulgaris | Cain457A3401 | An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300mg s.c. with or without previous exposure to systemic therapy | IV |
Psoriasis vulgaris | I1F-MC-RHBC | A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis with a Long-Term Extension Period | III |
Psoriasis vulgaris bei Kindern | CC-10004 PPSO-001 | A Phase 2, multicenter, open-label, study to assess the safety, tolerability and pharmakokinetics of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis | II |
Psoriasis vulgaris bei Kindern | CAIN457A2310 | A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis | III |
Chronisch spontane Urtikaria | QGE031C2201 | A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with hronic spontaneous urticaria (CSU) | IIb |
Chronisch spontane Urtikaria | CQGE031C2201E1 | An open label, multicenter, extention study to evaluate the Long-term safety of QGE031 240mg s.c. given every 4 weeks for 53 weeks in Cronic Spontaneous Urticaria patients who completed study CQGE031C2201 | IIb |
Hereditäre Angioödeme | Dyax DX-2930-03 | A multicenter, randomized, double-blind, placebo-controlled efficacy and safety study to evaluate DX-2930 for laong-term prophylaxis against acute attacks of hereditary angioedema (HAE) | III |
Hereditäre Angioödeme | Dyax DX-2930-04 | HELP Study Extension: An open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE) | III |
Atopische Dermatitis | R668-AD-1225 | A phase 3 confirmatory study investigating the efficacy and safty of Dupilumab monotherapy administered to adult patients with moderate to severe atopic Dermatitis | III |
Onychomykose | PM1331 | A multicenter, randomized, double-blind, parallel, vehicle-controlles study to evaluate the efficacy and safety of P-3058 10% nail solution in the treatment of Onychomycosis | III |
Pemphigus vulgaris | Pemphix WA29330 | A randomized, double-blind, double-dummy, active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris | III |
Akne vulgaris | RD.06.SPR.18251 | A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris | III |
Archiv
Hier finden Sie eine Auflistung vergangener Studien des CRC
, 4,0 MB)